Authors
Latest:
Dr. Ferris on Combining STING Agonists With Checkpoint Inhibitors in Head and Neck CancerRobert L. Ferris, MD, PhD, discusses combining STING agonists with checkpoint inhibitors in head and neck cancer.
Latest:
Dr. Jotte on the Low Rate of Screening in Lung CancerRobert M. Jotte, MD, PhD, medical director and co-chair of the USON Thoracic Committee at Rocky Mountain Cancer Centers, discusses the low rate of screening for lung cancer.
Latest:
Dr. Rifkin on Corneal Toxicities With Belantamab Mafodotin in Multiple MyelomaRobert M. Rifkin, MD, FACP, discusses corneal toxicities with belantamab mafodotin-blmf in multiple myeloma.
Latest:
Dr. Wenham on the Importance of Clinical Trials in Ovarian CancerRobert Wenham, MD, MS, FACOG, FACS, discusses the importance of clinical trials in ovarian cancer.
Latest:
Robert McCormack Explains the CellSearch CTC TestRobert McCormack, PhD, head, Technology Innovation, Janssen Diagnostics, LLC, explains the circulating tumor cell test CellSearch.
Latest:
Dr. Montal on Molecular Predictors of Recurrence With Adjuvant Sorafenib in HCCRobert Montal, MD, visiting researcher, Icahn School of Medicine, Mount Sinai Hospital, discusses biomarker findings of the phase III STORM trial, which explored adjuvant treatment with sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).
Latest:
Dr. Pirker on New Clinical Trial Designs in Lung CancerRobert Pirker, MD, Department of Medicine I, Medical University of Vienna, discusses novel clinical trial designs that researchers should use going forward in lung cancer.
Latest:
Dr. Kuske on APBI Via Multicatheter Interstitial BrachytherapyRobert R. Kuske, MD, radiation oncologist, Arizona Breast Cancer Specialists, discusses the analysis of the Pooled Registry of Multicatheter Interstitial Sites Experience, which examined the safety of accelerated partial breast irradiation via multicatheter interstitial brachytherapy.
Latest:
Loving Lemons Even When You Wanted OrangesRobert Ramirez, DO, FACP, details his path to clinical thoracic oncology after originally planning on entering the academic field early in his career.
Latest:
Navigating the EHR Marketplace How to Choose the Right EHR for Your Oncology PracticeNavigating the EHR marketplace can be dizzying, with numerous products available to choose from, including locally installed client/server systems that require server hardware, local networks, data backup, and IT support, as well as hosted, Web-based systems.
Latest:
Unmet Needs in the Management of Advanced RCCDrs Alter and Diamond muse about the unmet needs in advanced RCC treatment.
Latest:
Dr. Siegel on Induction Therapy for Head and Neck CancerRobert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses induction therapy for head and neck cancer.
Latest:
New Methods of Boosting Response to Bladder Cancer Immunotherapy ExploredAlthough bacillus Calmette-Guérin (BCG) therapy has significantly improved outcomes for patients with non–muscle invasive bladder cancer since its introduction nearly 40 years ago, there is a pressing need to enhance responses to BCG and to distinguish which patients would respond to treatment early on in the course of therapy.
Latest:
City Oncologist or Country Oncologist?There are multiple factors to consider when deciding whether to practice in an country or a city setting
Latest:
Models Pave the Way for Improved Outcomes in MedulloblastomaTo discover targeted therapies for the more common and severe types of medulloblastoma, a laboratory at Sanford Burnham Prebys Medical Discovery Institute has led efforts to develop genetically engineered mouse models and patient-derived xenografts for studying the molecular basis of the disease.
Latest:
Dr. Wong on Risk Factors for Hepatitis B-Associated HCCRobert Wong, MD, MS, assistant clinical professor of medicine, director of research and education, Division of Gastroenterology and Hepatology at Alameda Health System, Highland Hospital, discusses the risk factors of hepatitis B-associated hepatocellular carcinoma (HCC).
Latest:
Dr. Orlowski on Bortezomib Added to Lenalidomide and Dexamethasone for Multiple MyelomaRobert Z. Orlowski, MD, PhD, Department Chair ad interim, Department of Lymphoma/Myeloma, Division of Cancer Medicine, professor, Florence Maude Thomas Cancer Research Professorship, The University of Texas MD Anderson Cancer Center, discusses the phase III SWOG 0777 study, which examined the addition of bortezomib to lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with previously untreated multiple myeloma.
Latest:
Dr. Leon Ferre on Reasons to Explore Biosimilars in OncologyRoberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses reasons to explore biosimilars in oncology.
Latest:
Dr. Bordonaro on the Treatment of Advanced CRCRoberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses treatment options for patients with colorectal cancer who fail on oxaliplatin- and irinotecan-based chemotherapy.
Latest:
Dr. Pili on the Challenges of Translocation RCCRoberto Pili, MD, discusses clinical challenges in translocation renal cell carcinoma.
Latest:
Rituximab for Chronic Lymphocytic Leukemia in Treatment-Naïve and Treatment-Experienced PatientsA mixed treatment comparison demonstrated that FCR significantly prolonged PFS compared with all other treatments and significantly increased ORR compared with all other treatments.
Latest:
Dr Jones on Communication Between Community and Academic Oncologists in Cancer CareRobin Jones, MD, MRCP, discusses the importance of communication between community and academic oncologists in cancer care.
Latest:
Robin McConnell Discusses Nutrition in Cancer CareRobin McConnell, from John Theurer Cancer Center, Discusses Nutrition in Cancer Care
Latest:
Dr. Scherber Discusses Ruxolitinib Failure in MyelofibrosisRobyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses ruxolitinib (Jakafi) failure in patients with myelofibrosis (MF).
Latest:
Dr. Saw Discusses Study of Vitamin D in MelanomaRobyn Saw, FRACS, MS, MBBS, associate professor of surgery, The University of Sydney, discusses a study of vitamin D in melanoma.
